MerckMEX:MRK -2.27%72 Days Payable is 89.84 as of Mar. 2026, which is 4% below its 10-year median of 93.76. GuruFocus rates MEX:MRK with a GF Score™ of 72/100 and a GF Value™ of MXN2,079.60 (Fairly Valued). The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, Merck ranks worse than 53.69% on this metric.
Merck's average Accounts Payable for the
three
months ended in Mar. 2026 was MXN74,479 Mil. Merck's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN75,647 Mil.
Hence, Merck's Days Payable for the
three
months ended in Mar. 2026 was 89.84.
The historical rank and industry rank for Merck's Days Payable or its related term are showing as below:
MEX:MRK'
s Days Payable Range Over the Past 10 Years
Min: 69.46 Med: 93.76 Max: 119.68
Current: 85.47
During the past 13 years, Merck's highest Days Payable was 119.68. The lowest was 69.46. And the median was 93.76.
MEX:MRK's Days Payable is ranked worse than 53.69% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs MEX:MRK: 85.47
Merck's Days Payable
declined
from Mar. 2025 (105.99) to Mar. 2026 (89.84).
It may suggest that Merckaccelerated paying its suppliers.
Merck Days Payable Related Terms
Merck Days Payable Historical Data
* Premium members only.
The historical data trend for Merck's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MRK vs AMGN, ABBV, GILD: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Merck's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Merck's Days Payable distribution charts can be found below:
* The bar in red indicates where Merck's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Merck's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merck (MEX:MRK) has a Days Payable of 89.84 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Merck and its competitors. This is near median its historical median of 93.76. Over the past decade, Merck's Days Payable has ranged from 69.46 to 119.68. According to the industry distribution chart, Merck ranks #495 out of 922 companies in the Drug Manufacturers industry, placing it in the top 53.7%.
Is Merck's Days Payable too high?
Merck's current Days Payable of 89.84 is near median its 10-year median of 93.76. Over the past 10 years, this metric has ranged from a low of 69.46 to a high of 119.68. The Drug Manufacturers industry median Days Payable is 90.84. Merck's value of 89.84 is 1.1% below this industry median. Based on the distribution chart, Merck ranks #495 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Merck has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck's Days Payable compare to AMGN and ABBV?
According to the Drug Manufacturers industry distribution chart, Merck ranks #495 out of 922 companies for Days Payable. This places Merck in the lower half of its industry. The industry median Days Payable is 90.84. Merck's value of 89.84 is 1.1% below this benchmark. Historically, Merck's own Days Payable has ranged from 69.46 to 119.68 over the past decade. While the company's 10-year median is 93.76 vs. the industry median of 90.84, Merck has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merck's current Days Payable of 89.84 is 1.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Merck and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merck's current Days Payable is 89.84, which is near median its own 10-year median of 93.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Based on GuruFocus' analysis, Merck (MEX:MRK) is currently considered Fairly Valued. The stock's GF Value™ is MXN2,079.60, compared to a current price of MXN2,199.98 — trading 5.8% above its estimated fair value. The current Days Payable is 89.84, which is near median its 10-year median of 93.76 and 1.1% below the Drug Manufacturers industry median of 90.84. Merck's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Merck (MEX:MRK), the current Days Payable is 89.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merck (MEX:MRK) Overvalued in 2026?
Based on GuruFocus' analysis, Merck stock appears to be overvalued.
The current stock price of MXN2,199.98 is trading 5.8% above its estimated GF Value™ of MXN2,079.60.
GuruFocus considers Merck to be Fairly Valued.
Key valuation signals for MEX:MRK:
Days Payable: 89.84 (near median its 10-year median of 93.76)
GF Value™: MXN2,079.60 vs. price of MXN2,199.98 (5.8% above fair value)
Industry Position: 1.1% below the Drug Manufacturers median (#495 of 922)
No single metric tells the full story. See the MEX:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
72GF Score
Get the complete analysis for MEX:MRK
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MRK has been successfully added to your 
